Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: The adverse effects of antipsychotic agents can have a marked influence on medication adherence. In this study, we investigated the adverse events of antipsychotics that are less likely to be reported by patients and the reasons why such symptoms remain latent. Methods: Data were collected by interviewing patients using a subjective questionnaire, and the associations between unreported symptoms and background factors were investigated. Results: A total of 306 patients with schizophrenia or schizoaffective disorder were examined. Their major symptoms were daytime sleepiness (50.0%), weight gain (42.2%), and sexual dysfunction (38.9%). Sexual dysfunction was nominal significantly more common among the patients that had been treated with antipsychotic agent polypharmacy (odds ratio [OR], 2.14; 95% confidence interval [CI], 1.07 to 4.30), and was nominal significantly more common among outpatients (OR, 1.78; 95% CI, 1.02 to 3.13). Only approximately 30% of the patients had reported their symptoms to their physicians. Conclusion: Patients receiving antipsychotic treatment tolerate some symptoms and do not feel able to report them to their physicians. The most common reason for this is an insufficient patient-physician relationship. Sexual dysfunction is especially hard to identify because it is a delicate problem, and our findings demonstrate that subjective questionnaires are helpful for detecting such symptoms.
Abstract
Objective: The adverse effects of antipsychotic agents can have a marked influence on medication adherence. In this study, we investigated the adverse events of antipsychotics that are less likely to be reported by patients and the reasons why such symptoms remain latent. Methods: Data were collected by interviewing patients using a subjective questionnaire, and the associations between unreported symptoms and background factors were investigated. Results: A total of 306 patients with schizophrenia or schizoaffective disorder were examined. Their major symptoms were daytime sleepiness (50.0%), weight gain (42.2%), and sexual dysfunction (38.9%). Sexual dysfunction was nominal significantly more common among the patients that had been treated with antipsychotic agent polypharmacy (odds ratio [OR], 2.14; 95% confidence interval [CI], 1.07 to 4.30), and was nominal significantly more common among outpatients (OR, 1.78; 95% CI, 1.02 to 3.13). Only approximately 30% of the patients had reported their symptoms to their physicians. Conclusion: Patients receiving antipsychotic treatment tolerate some symptoms and do not feel able to report them to their physicians. The most common reason for this is an insufficient patient-physician relationship. Sexual dysfunction is especially hard to identify because it is a delicate problem, and our findings demonstrate that subjective questionnaires are helpful for detecting such symptoms.
참고문헌 (20)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Lacro JP, "Prevalence of and risk factors for medication nonadherence in patients with schizophrenia : a comprehensive review of recent literature", J Clin Psychiatry, 63, pp.892~909 (2002)
- Marder SR, "Risperidone in the treatment of schizophrenia", Am J Psychiatry, 151, pp.825~835 (1994)
- Fujimaki K, "Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia", PLoS One, 7, pp.e37087~ (2012)
- Zhang JP, "Efficacy and safety of individual secondgeneration vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis", Int J Neuropsychopharmacol, 16, pp.1205~1218 (2013)
- DE Hert M, "Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care", World Psychiatry, 10, pp.52~77 (2011)
- Gallego JA, "Safety and tolerability of antipsychotic polypharmacy", Expert Opin Drug Saf, 11, pp.527~542 (2012)
- Kapur S, "Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia", Am J Psychiatry, 157, pp.514~520 (2000)
- Geddes J, "Atypical antipsychotics in the treatment of schizophrenia : systematic overview and meta-regression analysis", BMJ, 321, pp.1371~1376 (2000)
- Ezewuzie N, "Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia", J Psychopharmacol, 20, pp.86~90 (2006)
- Shinfuku M, "How psychotropic polypharmacy in schizophrenia begins : a longitudinal perspective", Pharmacopsychiatry, 45, pp.133~137 (2012)
- Kanda Y, "Investigation of the freely available easy-to-use software 'EZR' for medical statistics", Bone Marrow Transplant, 48, pp.452~458 (2013)
- Hashimoto Y, "Effects of antipsychotic polypharmacy on sideeffects and concurrent use of medications in schizophrenic outpatients", Psychiatry Clin Neurosci, 66, pp.405~410 (2012)
- Yeon Won Park, "Antipsychotic-Induced Sexual Dysfunction and Its Management", The World Journal of Men's Health, 30(3), pp.153~159 (2012), 대한남성과학회
- Fujii A, "Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.288~293 (2010)
- Wieck A, "Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences", Br J Psychiatry, 182, pp.199~204 (2003)
- Baggaley M, "Sexual dysfunction in schizophrenia : focus on recent evidence", Hum Psychopharmacol, 23, pp.201~209 (2008)
- Malik P, "Sexual dysfunction in schizophrenia", Curr Opin Psychiatry, 20, pp.138~142 (2007)
- Yasui-Furukori N, "No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics", Hum Psychopharmacol, 27, pp.82~89 (2012)
- Brooks JO 3rd, "Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder : findings from the Systematic Treatment Enhancement Program for Bipolar Disorder", J Clin Psychiatry, 72, pp.240~247 (2011)